Immunology
Immune System Disease
64
Pipeline Programs↗
1
Active Trials↗
31
Companies Involved↗
Immune System Disease is a moderately active landscape with 64 programs across 31 companies. The most active players are GSK, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Johnson & Johnson. 27 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical29
Phase 16
Phase 21
Phase 31
Analysis
Modality Breakdown
65programs
Small molecule3249%
Monoclonal antibody2742%
Protein / enzyme58%
Cell therapy12%
Modality classified for 100% of 65 pipeline programs.
Analysis
Trial Status
1
clinical trials
Recruiting1 · 100%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)